Dinucleotide Compounds for HCV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infections lack effective and low-toxicity pharmaceutical agents, and there is a need for new treatments that can address the rising threat of flaviviridae infections.
Innovation Solution
Development of dinucleotide compounds, specifically those according to Formula I (N1-L-N2), which are 2'-methyl nucleotides linked by a divalent linker, offering remarkable efficacy and bioavailability for treating HCV and other flaviviridae infections, including chronic liver inflammation, cirrhosis, and acute hepatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for HCV infections are used, then treatment is provided, but effectiveness is insufficient and toxicity is high
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of nucleoside analogs through specific substitutions (2'-methyl groups, 2'-fluoro groups, O-alkyl modifications) to optimize the balance between antiviral effectiveness and host toxicity. These structural parameter changes enable the compound to achieve remarkable efficacy against HCV while maintaining low toxicity profiles.
Solution Approach 2:
The invention creates composite molecular structures by combining modified nucleoside units with specific divalent linkers (L) to form dinucleotide compounds. This composite approach, where two nucleoside moieties are connected through defined linker structures, produces a molecule with enhanced antiviral activity and improved safety profile compared to monomeric nucleoside analogs.
2Reliability
If existing nucleoside derivatives are used, then some antiviral activity is achieved, but bioavailability and efficacy are limited
Solution Approach 1:
The patent merges two nucleoside analog units into a single dinucleotide compound through a divalent linker, creating a bivalent antiviral agent. This merging strategy increases the quantity of active antiviral moieties delivered to the target, thereby enhancing efficacy and bioavailability while maintaining favorable pharmacokinetic properties.
3Reliability
If new effective agents are developed, then treatment efficacy improves, but complexity of compound structure increases
Solution Approach 1:
The complex dinucleotide compound is segmented into recognizable and systematic components: modified nucleoside units with specific substituents (2'-methyl, 2'-fluoro, O-alkyl groups) connected through defined divalent linkers. This segmentation approach allows the complex structure to be designed, synthesized, and characterized in a modular fashion, making the complexity manageable while achieving superior efficacy.
Data Source
AI summary
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds comprise two 2 '-methyl nucleotides linked according to Formula (I): N1 - L - N2 or a pharmaceutically acceptable salt, ester, solvate, stereoisomer, isomeric form, tautomeric form or polymorphic form thereof; wherein N1, L and N2 are as described herein.